A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

Schwartz, Cindy L.; Constine, Louis S.; Villaluna, Doojduen; London, Wendy B.; Hutchison, Robert; Sposto, Richard; Lipshultz, Steven E.; Turner, Chanda; deAlarcon, Pedro A.; Chauvenet, Allen R.

doi:10.1182/blood-2008-10-184143

Cited by 191 publications

(240 citation statements)

References 41 publications

(51 reference statements)

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…[61] Children Oncology Grup, 1997-2001'de orta ve yüksek riskli hastalarda risk adapte, cevap ilişki-li olarak P9425 çalışması ile yoğun KT ile tümör stabilitesini ve hızlı tümör yıkımını sağlayarak tedaviye erken cevap verenlerde kümülatif dozun azaltılması amaçlı ABVE-PC'li (adriamisin, bleomisin, vinkristin, etoposid, prednizon, cyclofosfamid) kemoterapi ve sonrasında IFRT uyguladı. [62] Bu tedavi ile beş yıllık EFS'yi %84; OS'yi %95 olarak saptayarak, yüksek riskli hastalarda yoğun kemoterapi uygulaması ile erken cevabın sağlana-bileceği ve kümülatif dozun azaltılabileceği görül-dü. [62] Children's Cancer Group, 1999-2001'de C59704 çalışması ile yüksek riskli hastalarda erken dönemde yoğun KT (BEACOPP; bleomisin, etoposid, adriamisin, cyclofosfamid, vinkristin, prednizon, prokarbazin) uygulanması ile sağ kalım ve toksisite oranlarına bakdığı çalışmada, cinse bağlı olarak geç dönemde oluşabilecek toksisitelerin azaltılması amacı ile iki-dört kür kemoterapi sonrası hızlı cevap veren hastalarda cinse özgü ola-…”

Section: Kaynakunclassified

“…[62] Bu tedavi ile beş yıllık EFS'yi %84; OS'yi %95 olarak saptayarak, yüksek riskli hastalarda yoğun kemoterapi uygulaması ile erken cevabın sağlana-bileceği ve kümülatif dozun azaltılabileceği görül-dü. [62] Children's Cancer Group, 1999-2001'de C59704 çalışması ile yüksek riskli hastalarda erken dönemde yoğun KT (BEACOPP; bleomisin, etoposid, adriamisin, cyclofosfamid, vinkristin, prednizon, prokarbazin) uygulanması ile sağ kalım ve toksisite oranlarına bakdığı çalışmada, cinse bağlı olarak geç dönemde oluşabilecek toksisitelerin azaltılması amacı ile iki-dört kür kemoterapi sonrası hızlı cevap veren hastalarda cinse özgü ola-…”

Section: Kaynakunclassified

“…C5942 [60] Tüm risk grupları 826 10 yıllık EFS %83.5 10 yıllık OS %92.5 P9425 [62] Orta-yüksek risk 216 5 yıllık EFS %84 5 yıllık OS %95 P9426 [61] Düşük risk 255 8 yıllık EFS %86.3 8 yıllık OS %96.5 C59704 [64] Yüksek risk 98 5 yıllık EFS %94 5 yıllık OS %97…”

Section: Risk Grup Hasta Sayısı Sonuçunclassified

“…[63] Cinse bağlı geç dönemde oluşabilecek toksisitelerin takibi halen yapılmakta olan çalışmada altı yıllık EFS %94 olarak saptanarak [64] daha önce yapılmış olan yüksek riskli hastalardaki tedavi protokollerinin sonuçlarından daha iyi bulundu. [47,48,60,62] Bu çalışmada yazarlar yüksek riskli HL'li hastalarda "cevap ilişkili tedavi" ile erken yoğun tedaviye hızlı cevap verenlerde daha düşük yoğunlukta tedavi ile devam edilmesinin yüksek sağ kalım elde edilmesinde etkili olduğunu belirtilmektedirler. [64] St. Jude/Stanford/Dana Farber'da düşük riskli HL'li hastalarda tedavinin ve toksisitenin azaltıl-ması amaçlı alkilleyici ajan, bleomisin ve etoposid kullanılmadan VAMP'li (vinkristin, adriamisin, methotreksat, prednizolon) KT ve sonrasında tutulu alan düşük doz radyoterapinin uygulandığı 1990-2000 yılları arasındaki çalışmada 10 yıllık OS %96.1; EFS %89.4 olarak saptandı.…”

Section: Risk Grup Hasta Sayısı Sonuçunclassified

See 3 more Smart Citations

Treatment of Hodgkin’s lymphoma in children

Kebudi¹

2015

TJ Oncol

View full text Add to dashboard Cite

With the advances in current diagnostics and treatment modalities the survival in children with Hodgkin's lymphoma have significantly increased. The aim of the treatment nowadays is administering the most effective and least toxic treatment. This has leaded to "risk adapted, response and gender modified" treatments. In this review, the treatment modalities and results used in Hodgkin's lymphoma in children within decades have been assessed.

show abstract

Section: Kaynakunclassified

Section: Risk Grup Hasta Sayısı Sonuçunclassified

See 2 more Smart Citations

Treatment of Hodgkin’s lymphoma in children

Kebudi¹

2015

TJ Oncol

View full text Add to dashboard Cite

show abstract

“…26,27 In the POG study, with a median follow-up of 5.2 years, three patients developed AML and one osteosarcoma. 28 In the COG study, with a median follow-up of 6.3 years, two patients developed AML.…”

Section: Pediatric Studies Including Adolescents and Young Adultsmentioning

confidence: 99%

Hodgkin’s Lymphoma in Adolescents and Young Adults

Rodríguez¹,

Punnett²

2012

Oncology &Amp; Hematology Review (US)

View full text Add to dashboard Cite

Adolescents and young adults (AYAs) are defined as those individuals between the ages of 15 and 39 years.1 AYAs with cancer are considered a vulnerable group, in large part due to psychosocial challenges in this population, including lack of insurance, low rates of clinical trial enrollment, issues pertaining to independence, and concerns about body image and fertility. Hodgkin's lymphoma (HL) is the most common cancer observed among AYAs. 6 There is a slight overall male predominance in this age group, with a male:female ratio of 1.2. [6][7][8][9] Prior history of infection with Epstein-Barr virus (EBV) has been associated with an increased risk of HL. 10 Among AYAs, however, molecular studies show that EBV is related to HL in only a minority of cases and that it is unlikely to play a major etiologic role. 11,12The most common histological subtype of HL among the adolescent and young adult (AYA) population is nodular sclerosing classical HL, occurring in 50-80 % of patients. [7][8][9]13,14 Over the past decades, the prognosis of HL has dramatically improved, 15 but the optimal treatment of AYA patients remains undefined and patients continue to be treated on many different regimens with either pediatric or adult protocols. We will examine available literature regarding outcomes for the AYA population and discuss the therapy-related long-term sequelae. Studies Examining Adolescent and Young Adult OutcomesStudies focusing specifically on AYAs diagnosed with HL are scarce. Reviewing the literature, we found eight studies, and their main characteristics are summarized in The results of these studies should be interpreted with caution, however, as historical practices no longer considered appropriate, such as staging laparotomy and splenectomy, were employed, as well as older chemotherapy and radiotherapy protocols. AbstractAdolescents and young adults (AYAs) are defined as those individuals between the ages of 15 and 39 years. Hodgkin's lymphoma (HL) is the most common cancer observed in AYAs. Over the last two decades, significant improvements in both survival from HL and the reduction of therapy-related late effects have resulted from the work of collaborative study groups in pediatric and adult domains. The adolescent and young adult (AYA) population falls between these domains. AYA patients are in a critical developmental transition, with significant psychosocial challenges that may impact on the outcome of the primary treatment as well as on the medical care and surveillance of long-term sequelae in survivors. This article will examine available literature regarding outcomes for HL in the AYA population, identifying issues unique to this group, therapeutic options, and specific concerns in follow-up. KeywordsHodgkin's lymphoma, therapy, late effects, adolescents and young adults, second malignancies Disclosure:The authors have no conflicts of interest to declare.

show abstract

Cardioprotective interventions for cancer patients receiving anthracyclines

Dalen

Caron

Dickinson

et al. 2011

Cochrane Database of Systematic Reviews

308

226

View full text Add to dashboard Cite

No definitive conclusions can be made about the efficacy of cardioprotective agents for which pooling of results was impossible. Dexrazoxane prevents heart damage and no evidence for a difference in response rate or survival between the dexrazoxane and control groups was identified. The evidence available did not allow us to reach any definite conclusions about adverse effects. We conclude that if the risk of cardiac damage is expected to be high, it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines. However, clinicians should weigh the cardioprotective effect of dexrazoxane against the possible risk of adverse effects for each individual patient.

show abstract

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

Cited by 191 publications

References 41 publications

Treatment of Hodgkin’s lymphoma in children

Treatment of Hodgkin’s lymphoma in children

Hodgkin’s Lymphoma in Adolescents and Young Adults

Cardioprotective interventions for cancer patients receiving anthracyclines

Contact Info

Product

Resources

About